Efficacy of high-dose therapy and hematopoietic stem cell transplantation for mantle cell lymphoma

American Journal of Hematology

Volumn 81, Issue 7, 2006, Pages 519-524

  Laudi, Noel ^a   Arora, Mukta ^a   Burns, Linda ^a   McGlave, Philip ^a   Miller, Jeffrey ^a   Bohac, Gerald ^a   Rogers, Tyson ^a   Barker, Juliet ^a   Coad, James ^a   Weisdorf, Daniel ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Allogeneic; Autologous; Mantle cell lymphoma; Stem cell transplant

Indexed keywords

CYCLOSPORIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYELOABLATIVE AGENT; RITUXIMAB;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER SURVIVAL; CELL SURVIVAL; CHROMOSOME TRANSLOCATION; CLINICAL ARTICLE; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; MALE; MANTLE CELL LYMPHOMA; PRIORITY JOURNAL; REMISSION; STEM CELL TRANSPLANTATION; TUMOR SUPPRESSOR GENE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SEPSIS; TIME FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 33745727035     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20646     Document Type: Article

References (30)

1. Weisenburger DD, Kim H, Rappaporrt H. Mantle-zone lymphoma. A follicular variant of intermediate lymphocytie lymphoma. Cancer 1982;49:1429-1438.
2. Palutke M, Eisenberg L, Mirchandani I, et al. Malignant lymphoma of small cleaved lymphocytes of the follicular mantle zone. Blood 1982;59:317-322.
3. Banks PM, Chan J, Cleary ML, et al. Mantle cell lymphoma: a proposal for unification of morphologic, immunologic and molecular data. Am J Surg Pathol 1992;16:637-640.
4. Segal GH, Masib AS, Fox AC, et al. CD5-expressing B-cell non-Hodgkin's lymphomas with bcl-1 gene rearrangement have a relatively homogenous immunophenotype and are associated with an overall poor prognosis. Blood 1995;85:1570-1575.
5. Weisenburger DD, Armitage JO. Mantle cell lymphoma-an entity comes of age. Blood 1996;87:4483-4494.
6. Velders GA, Kluin-Nelemans JC, De Boer CJ, et al. Mantle-cell lymphoma: a population-based clinical study. J Clin Oncol 1996;14:1269-1274.
7. Zucca E, Fontana S, Roggero E, et al. Treatment and prognosis of centrocytic (mantle cell) lymphoma: a retrospeclive analysis of twenty-six patients treated in one institution. Leuk Lymphoma 1994;13:105-110.
8. Howard OM, Gribben JG, Neuberg DS, et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002;20:1288-1294.
9. Foran JM, Rohatiner AZ, Cunningham D, et al. European phase 11 study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphoeytic lymphoma. J Clin Oncol 2000;18:317-324.
10. Freedman AS, Neuberg D, Gribben JG, et al. High dose chemoradiotherapy and ami-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle cell lymphoma: no evidence for long term remission. J Clin Oncol 1998;16:13-18.
11. Khouri IF, Romaguera JP, Pugh JL, et al. Preliminary report of a new active regimen for aggressive mantle cell lymphoma. Br J Haematol 1998;102:240-241.
12. Rosenberg SA, et al. Validity of the Ann Arbor staging classification for the non-Hodgkin's lymphomas. Cancer Treat Rep 1977;61:1023-1027.
13. Shipp MA, et al. Prognostic factors in aggressive non-Hodgkin's lymphoma: who has "high-risk" disease? Blood 1994;83:1165-1173.
14. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
15. Lin DY. Non-parametric inference for cumulative incidence functions in competing risks studies. Stat Med 1997;16:901-910.
16. Klein JP, Moeschbcrger ML. Survival analysis: techniques for censored and truncated data. Springer-Verlag: New York, 1997; Section 7.3.
17. Cox DR. Regression models and life tables. J R Stat Soc B 1972;34:187-220.
18. Romaguera JE, Fayad L, Rodriquez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005;23:7013-7023.
19. Oinonen R, Jantunen E, Itala M. et al. Autologous stem cell transplantation in patients with mantle cell lymphoma. Leuk Lymphoma 2002;43:1229-1237.
20. Ganti AK, Bierman PJ, Lynch JC. et al. Long term disease free survival in patients with mantle cell lymphoma following hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2004; Abstract 55.
21. Vandenberghe E, Ruiz de Elvira C, Loberiza FR, et al. Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. Br J Haematol 2003;120:793-800.
22. Molina A, Kraft D, Carter N, et al. Autologous stem cell transplantation (ASCT) for mantle cell lymphoma (MCL): a report of 69 patients from CiIy of Hope (COH) and Stanford [abstract]. Blood 2002;100:680a.
23. Räty R, Franssila K, Joensuu H, Teerenhovi L, Elonen E. Ki-67 expression level, histological subtype, and the International Prognostic Index as outcome predictors in mantle cell lymphoma. Eur J Haematol 2002;69:11-20.
24. Mangel J, Leitch HA, Connors JM, et al. Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis. Ann Oncol 2004;15:283-290.
25. Delarue R, Haioun C, Brice P, et al. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a pilot study from the GELA. 2004 ASCO Annual Meeting. Abstract No: 6529.
26. Adkins D, Brown R, Goodnough LT, et al. Treatment of resistant mantle cell lymphoma with allogeneic bone marrow transplantation. Bone Marrow Transplant 1998;21:97-99.
27. Khouri IF, Lee MS, Romaguera J, et al. Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy. Ann Oncol 1999;10:1293-1299.
28. Khouri IF, Lee MS, Saliba RM, et al. Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol 2003;21:4407-4412.
29. Corradini P, Corrado T, Olivieri A, et al. Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. Blood 2002;99:75-82.
30. Maris M, Sandmaier B, Storer B, et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 2004;104:3535-3542.